Codon Adaptation Index (CAI) of your gene is 0.81. A CAI of 1.0 is considered ideal while a CAI of >0.8 is rated as good for expression in the desired […]
All posts by signagen - 30. page
Codon Adaptation Index
The Codon Adaptation Index (CAI) is the most widespread technique for analyzing Codon usage bias. As opposed to other measures of codon usage bias, such as the ‘effective number of […]
Codon usage bias
Codon usage bias refers to differences in the frequency of occurrence of synonymous codons in coding DNA. A codon is a series of three nucleotides (a triplet) that encodes a […]
How to optimize a synthetic gene for a specific specie
Refer to https://www.idtdna.com/CodonOpt
Managing MicroRNAs with Vector-Encoded Decoy-Type Inhibitors
A rapidly growing understanding of the complex circuitry of microRNA (miRNA)-mediated gene regulation is attracting attention to miRNAs as new drug targets. Targeted miRNA suppression is achieved in a sequence-specific […]
Going viral: chimeric antigen receptor T-cell therapy for hematological malignancies.
On July 1, 2014, the United States Food and Drug Administration granted ‘breakthrough therapy’ designation to CTL019, the anti-CD19 chimeric antigen receptor T-cell therapy developed at the University of Pennsylvania. […]
The CAR T-Cell Race
Tumor-targeting T-cell therapies are generating remarkable remissions in hard-to-beat cancers—and attracting millions of dollars of investment along the way. By Vicki Brower | April 1, 2015 BUILDING A BETTER T-CELL: […]
First Success With CAR T-Cells in a Solid Tumor
Chimeric antigen-receptor (CAR) T-cell therapy has repeatedly provided dramatic results in patients with hematologic malignancies. Now comes the first success story of CAR T-cell therapy in a solid tumor — […]
CAR T-CELL BIOTECH IPOs
Company Date Value Kite Pharma June 2014 $134.1 million Bellicum December 2014 $160 million Juno December 2014 $264.6 million Cellectis March 2015 $228 million